循环microRNA谱作为分化型甲状腺癌复发的潜在生物标志物
本研究比较了30例分化型甲状腺癌患者(14例复发/持续疾病 vs 16例完全缓解)的血清microRNA谱,并观察rhTSH刺激前后的变化。下一代测序和qPCR验证未发现已知microRNA在有无复发/持续疾病或rhTSH刺激前后存在一致差异,但发现2个新推测microRNA在复发/持续疾病患者血清中随rhTSH刺激升高,并在TSH刺激的细胞中经qPCR证实上调。作者认为已知microRNA不能作为甲状腺癌复发的循环标志物,但新microRNA分子可能与甲状腺癌发病机制相关。
要点
- 已知血清microRNA在复发/持续疾病与完全缓解患者间无一致差异。
- rhTSH刺激前后已知microRNA血清谱无一致差异。
- 2个新推测microRNA在复发/持续疾病患者血清中随rhTSH刺激升高并经qPCR证实。
核心结论
- 本研究未提供证据表明已知microRNA可作为甲状腺癌复发的循环标志物。
- 作者认为新microRNA分子可能与甲状腺癌发病机制相关。
研究设计与样本
- 获取30例分化型甲状腺癌患者血清样本,其中14例复发/持续疾病、16例完全缓解。
- 采用下一代测序定义microRNA组,并使用2种不同平台进行定量PCR验证。
- 开展横断面研究比较有无复发/持续疾病患者的血清microRNA谱,并开展纵向研究观察rhTSH刺激前后的差异。
- 在人类甲状腺癌细胞系TPC-1、FTC-133和OCUT-2中研究所选microRNA对TSH刺激的反应。
主要发现
- 未能在有无复发/持续疾病患者之间或rhTSH刺激前后证明已知microRNA的血清谱存在任何一致差异。
- 测序数据揭示2个新推测microRNA在复发/持续疾病患者血清中随rhTSH刺激升高。
- qPCR进一步证实这些新推测microRNA在血清和TSH刺激细胞中均上调。
- 还发现独立于TSH水平的血清microRNA可作为管家基因的良好候选。
关键数值与推荐
- 已知microRNA在复发/持续疾病与完全缓解患者间无一致血清谱差异。
- rhTSH刺激前后已知microRNA血清谱无一致差异。
- 2个新推测microRNA在复发/持续疾病患者血清中随rhTSH刺激升高,并在TSH刺激细胞中经qPCR证实上调。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Circulating microRNAs (miRNAs) are emerging biomarkers of thyroid cancer. OBJECTIVE: This study sought to identify the profile of circulating miRNAs and its response to human recombinant TSH (rhTSH) in thyroid cancer patients with recurrent/persistent disease. METHODS: We obtained serum samples from 30 patients with differentiated thyroid cancer, 14 with recurrent/persistent disease and 16 with complete remission. We used next-generation sequencing to define the miRnomes along with a comprehensive quantitative PCR (qPCR) validation using 2 different platforms. We made a transversal study by comparing serum miRNA profiles of patients with or without recurrent/persistent disease and a longitudinal study looking at differences before and after rhTSH stimulation. Selected miRNAs were then studied in human thyroid cancer cell lines TPC-1, FTC-133, and OCUT-2 in response to TSH stimulation. RESULTS: We could not demonstrate any consistent differences in serum profiles of known miRNAs between patients with and without recurrent/persistent disease or before and after rhTSH stimulation. However, our sequencing data revealed 2 putative novel miRNAs that rise with rhTSH stimulation in the serums of patients with recurrent/persistent disease. We further confirmed by qPCR the upregulation of these putative miRNAs both in serums and in TSH-stimulated cells. We also show miRNAs that are good candidates for housekeeping genes in the serum of patients independently of the levels of TSH. CONCLUSIONS: The present study does not provide evidence that known miRNAs can be used as circulating markers for recurrence of thyroid cancer. However, we suggest that novel miRNA molecules may be related to thyroid cancer pathogenesis.
引用
- Jankovic Miljus J, Guillén-Sacoto MA, Makiadi-Alvarado J, et al. Circulating MicroRNA Profiles as Potential Biomarkers for Differentiated Thyroid Cancer Recurrence. J Clin Endocrinol Metab. 2022. PMID: 35022762. doi:10.1210/clinem/dgac009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。